The DOI matches its Crossref record; 54 of the 54 references it cites were found in a registry or an index.
Humanization of a recombinant monoclonal antibody to produce a therapeutic HER dimerization inhibitor, pertuzumab
Open accessOverview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Statistical principles in experimental design.
Winer, B. J. (1962) · McGraw-Hill Book Company · doi:10.1037/11774-000 · Cited by 26,755
Rapid and efficient site-specific mutagenesis without phenotypic selection.
Kunkel, T. A. (1985) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.82.2.488 · Cited by 7,206
Untangling the ErbB signalling network
Yarden, Y., & Sliwkowski, M. X. (2001) · Nature Reviews Molecular Cell Biology · doi:10.1038/35052073 · Cited by 6,974
Self-citationCharacteristics of a human cell line transformed by DNA from human adenovirus type 5
Graham, F. L., Russell, W. C., Smiley, J., & Nairn, R. (1977) · Journal of General Virology · doi:10.1099/0022-1317-36-1-59 · Cited by 4,793
Sequences of proteins of immunological interest
(1984) · Analytical Biochemistry · doi:10.1016/0003-2697(84)90805-4 · Cited by 3,363
New Tables for Multiple Comparisons with a Control
Dunnett, C. W. (1964) · Biometrics · doi:10.2307/2528490 · Cited by 3,113
Kris, M. G., Natale, R. B., Herbst, R. S., Lynch, Jr., Prager, D., Belani, C. P., Schiller, J. H., Kelly, K., Spiridonidis, H., Sandler, A., et al. (2003) · JAMA · doi:10.1001/jama.290.16.2149 · Cited by 2,517
Statistical Principles in Experimental Design
(2003) · Wiley Series in Probability and Statistics · doi:10.1002/0471458503.ch4 · Cited by 2,325
Humanization of an anti-p185HER2 antibody for human cancer therapy.
Carter, P., Presta, L., Gorman, C. M., Ridgway, J. B., Henner, D., Wong, W. L., Rowland, A. M., Kotts, C., Carver, M. E., & Shepard, H. M. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.10.4285 · Cited by 1,918
Self-citationStructure of the extracellular region of HER2 alone and in complex with the Herceptin Fab
Cho, H.-S., Mason, K., Ramyar, K. X., Stanley, A. M., Gabelli, S. B., Denney, D. W., & Leahy, D. J. (2003) · Nature · doi:10.1038/nature01392 · Cited by 1,612
Presta, L. G., Chen, H., O'Connor, S. J., Chisholm, V., Meng, Y. G., KRUMMEN, L. A., Winkler, M., & Ferrara, N. (1997) · PubMed · Cited by 1,608
Self-citationGraus-Porta, D. (1997) · The EMBO Journal · doi:10.1093/emboj/16.7.1647 · Cited by 1,590
Conformations of immunoglobulin hypervariable regions
Chothia, C., Lesk, A. M., Tramontano, A., Levitt, M., Smith-Gill, S. J., Air, G., Sheriff, S., Padlan, E. A., Davies, D., Tulip, W. R., et al. (1989) · Nature · doi:10.1038/342877a0 · Cited by 1,185
Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex
Franklin, M. C., Carey, K. D., Vajdos, F. F., Leahy, D. J., de Vos, A. M., & Sliwkowski, M. X. (2004) · Cancer Cell · doi:10.1016/s1535-6108(04)00083-2 · Cited by 1,120
Self-citationPérez-Soler, R., Chachoua, A., Hammond, L. A., Rowinsky, E. K., Huberman, M., Karp, D., Rigas, J., Clark, G. M., Santabárbara, P., & Bonomi, P. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.057 · Cited by 1,070
Tzahar, E., Waterman, H., Chen, X., Levkowitz, G., Karunagaran, D., Lavi, S., Ratzkin, B. J., & Yarden, Y. (1996) · Molecular and Cellular Biology · doi:10.1128/mcb.16.10.5276 · Cited by 1,036
An Open-and-Shut Case? Recent Insights into the Activation of EGF/ErbB Receptors
Burgess, A. W., Cho, H.-S., Eigenbrot, C., Ferguson, K. M., Garrett, T. P. J., Leahy, D. J., Lemmon, M. A., Sliwkowski, M. X., Ward, C. W., & Yokoyama, S. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00350-2 · Cited by 909
Self-citationErbB2 is essential in the prevention of dilated cardiomyopathy
Crone, S. A., Zhao, Y.-Y., Fan, L., Gu, Y., Minamisawa, S., Liu, Y., Peterson, K. L., Chen, J., Kahn, R., Condorelli, G., et al. (2002) · Nature Medicine · doi:10.1038/nm0502-459 · Cited by 903
Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth
Agus, D. B., Akita, R. W., Fox, W. D., Lewis, G. D., Higgins, B., Pisacane, P. I., Lofgren, J. A., Tindell, C., Evans, D. P., Maiese, K., et al. (2002) · Cancer Cell · doi:10.1016/s1535-6108(02)00097-1 · Cited by 873
Self-citationPinkas-Kramarski, R., Soussan, L., Waterman, H., Levkowitz, G., Alroy, I., Klapper, L., Lavi, S., Seger, R., Ratzkin, B. J., Sela, M., et al. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00603.x · Cited by 769
Garrett, T. P. J., McKern, N. M., Lou, M., Elleman, T. C., Adams, T. E., Lovrecz, G. O., Kofler, M., Jorissen, R. N., Nice, E. C., Burgess, A. W., et al. (2003) · Molecular Cell · doi:10.1016/s1097-2765(03)00048-0 · Cited by 613
The ErbB receptors and their role in cancer progression
Holbro, T. (2003) · Experimental Cell Research · doi:10.1016/s0014-4827(02)00099-x · Cited by 608
Cooperative signaling of ErbB3 and ErbB2 in neoplastic transformation and human mammary carcinomas.
Alimandi, M., Romano, A., Curia, M. C., Muraro, R., Fedi, P., Aaronson, S. A., Fiore, P. P. D., & Kraus, M. H. (1995) · PubMed · Cited by 548
Human anti-murine immunoglobulin responses in patients receiving monoclonal antibody therapy.
Schroff, R. W., Foon, K. A., Beatty, S. M., Oldham, R. K., & Morgan, A. C. (1985) · PubMed · Cited by 488
Humanization of an antibody directed against IgE.
Presta, L. G., Lahr, S. J., Shields, R. L., Porter, J. P., Gorman, C. M., Fendly, B. M., & Jardieu, P. M. (1993) · The Journal of Immunology · doi:10.4049/jimmunol.151.5.2623 · Cited by 474
Self-citationHeregulin‐dependent regulation of HER2/neu oncogenic signaling by heterodimerization with HER3.
Wallasch, C., Weiss, F. U., Niederfellner, G., Jallal, B., Issing, W., & Ullrich, A. (1995) · The EMBO Journal · doi:10.1002/j.1460-2075.1995.tb00101.x · Cited by 406
FENDLY, B. M., Winget, M., Hudziak, R. M., Lipari, M. T., Napier, M. A., & Ullrich, A. (1990) · PubMed · Cited by 403
Agus, D. B., Gordon, M. S., Taylor, C., Natale, R. B., Karlan, B., Mendelson, D. S., Press, M. F., Allison, D. E., Sliwkowski, M. X., Lieberman, G., et al. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.03.184 · Cited by 390
Self-citationBinding specificities and affinities of egf domains for ErbB receptors
Jones, J. T., Akita, R. W., & Sliwkowski, M. X. (1999) · FEBS Letters · doi:10.1016/s0014-5793(99)00283-5 · Cited by 381
Self-citationLeyland-Jones, B., Gelmon, K., Ayoub, J.-P., Arnold, A., Verma, S., Dias, R., & Ghahramani, P. (2003) · Journal of Clinical Oncology · doi:10.1200/jco.2003.12.109 · Cited by 293
ErbB-1 and ErbB-2 Acquire Distinct Signaling Properties Dependent upon Their Dimerization Partner
Olayioye, M. A., Graus-Porta, D., Beerli, R. R., Rohrer, J., Gay, B., & Hynes, N. E. (1998) · Molecular and Cellular Biology · doi:10.1128/mcb.18.9.5042 · Cited by 262
Tramontano, A., Chothia, C., & Lesk, A. M. (1990) · Journal of Molecular Biology · doi:10.1016/s0022-2836(05)80102-0 · Cited by 236
Essential Roles of Her2/erbB2 in Cardiac Development and Function
Negro, A. (2004) · Recent Progress in Hormone Research · doi:10.1210/rp.59.1.1 · Cited by 220
Eigenbrot, C., Randal, M., Presta, L., Carter, P., & Kossiakoff, A. A. (1993) · Journal of Molecular Biology · doi:10.1006/jmbi.1993.1099 · Cited by 185
Self-citationTargeting cyclooxygenase 2 and HER-2/neu pathways inhibits colorectal carcinoma growth
Mann, M., Sheng, H., Shao, J., Williams, C. S., Dubois, R. N., Pisacane, P. I., & Sliwkowski, M. X. (2001) · Gastroenterology · doi:10.1053/gast.2001.24844 · Cited by 179
Self-citationKeely, S. J., Uribe, J. M., & Barrett, K. E. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.42.27111 · Cited by 168
Suter, T. M., Cook-Bruns, N., & Barton, C. (2004) · The Breast · doi:10.1016/j.breast.2003.09.002 · Cited by 166
Enhanced Drug Resistance in Cells Coexpressing ErbB2 with EGF Receptor or ErbB3
Chen, X., Yeung, T. K., & Wang, Z. (2000) · Biochemical and Biophysical Research Communications · doi:10.1006/bbrc.2000.3731 · Cited by 151
Interspecies scaling and comparisons in drug development and toxicokinetics
Ings, R. M. J. (1990) · Xenobiotica · doi:10.3109/00498259009046839 · Cited by 151
Werther, W., González, T., O'Connor, S. L., McCabe, S., Chan, B., Hotaling, T. E., Champe, M., Fox, J. A., Jardieu, P. M., Berman, P. W., et al. (1996) · The Journal of Immunology · doi:10.4049/jimmunol.157.11.4986 · Cited by 148
Self-citationDifferential Regulation of Tumor Angiogenesis by Distinct ErbB Homo- and Heterodimers
Yen, L., Benlimame, N., Nie, Z.-R., Xiao, D., Wang, T., Moustafa, A. A., Esumi, H., Milanini, J., Hynes, N. E., Pagès, G., et al. (2002) · Molecular Biology of the Cell · doi:10.1091/mbc.e02-02-0084 · Cited by 146
Neuregulin-1 Activates the JAK-STAT Pathway and Regulates Lung Epithelial Cell Proliferation
Liu, J., & Kern, J. A. (2002) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.4850 · Cited by 132
Transient production of proteins using an adenovirus transformed cell line
Gorman, C., Gies, D. R., & McCray, G. (1990) · Cited by 122
Vajdos, F. F., Adams, C. W., Breece, T., Presta, L. G., de Vos, A. M., & Sidhu, S. S. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00264-4 · Cited by 118
Self-citationInhibition of vascular endothelial growth factor in the treatment of colorectal cancer
Fernando, N., & Hurwitz, H. I. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)70024-4 · Cited by 111
Lee, H., Akita, R. W., Sliwkowski, M. X., & Maihle, N. J. (2001) · PubMed · Cited by 96
Self-citationDesign and analysis of single-factor experiments.
Winer, B. J. (1962) · McGraw-Hill Book Company · doi:10.1037/11774-003 · Cited by 84
Inhibition of ligand-mediated HER2 activation in androgen-independent prostate cancer.
Mendoza, N., Phillips, G. D. L., Silva, J., SCHWALL, R. H., & Wickramasinghe, D. (2002) · PubMed · Cited by 79
Inhibition of vascular endothelial growth factor in the treatment of colorectal cancer
Fernando, N. H., & Hurwitz, H. I. (2003) · Seminars in Oncology · doi:10.1016/s0093-7754(03)00124-6 · Cited by 62
Eigenbrot, C. W., González, T., Mayeda, J., Carter, P. M., Werther, W., Hotaling, T. E., Fox, J., & Kessler, J. (1994) · Proteins Structure Function and Bioinformatics · doi:10.1002/prot.340180107 · Cited by 54
Sequence Plasticity in the Antigen-binding Site of a Therapeutic Anti-HER2 Antibody
Gerstner, R. B., Carter, P. M., & Lowman, H. B. (2002) · Journal of Molecular Biology · doi:10.1016/s0022-2836(02)00677-0 · Cited by 46
A potential role for activated HER-2 in prostate cancer.
Agus, D. B., Akita, R. W., Fox, W. D., Lofgren, J. A., Higgins, B., Maiese, K., Scher, H. I., & Sliwkowski, M. X. (2000) · PubMed · Cited by 41
Self-citationXiang, J., Sha, Y., Jia, Z., Prasad, L. G., & Delbaere, L. T. J. (1995) · Journal of Molecular Biology · doi:10.1006/jmbi.1995.0560 · Cited by 39
ELISA for quantitation of the extracellular domain of p185HER2 in biological fluids
Sias, P. E., Kotts, C. E., Vetterlein, D., Shepard, M., & Wong, W. L. (1990) · Journal of Immunological Methods · doi:10.1016/0022-1759(90)90400-p · Cited by 34
Cited by
The ErbB/HER family of protein-tyrosine kinases and cancer
Roskoski, R. (2014) · Pharmacological Research · doi:10.1016/j.phrs.2013.11.002 · Cited by 1,353
Properties of Human IgG1s Engineered for Enhanced Binding to the Neonatal Fc Receptor (FcRn)
Dall'Acqua, W. F., Kiener, P. A., & Wu, H. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m604292200 · Cited by 646
Baselga, J., Gelmon, K. A., Verma, S., Wardley, A., Conte, P., Miles, D., Bianchi, G., Cortes, J., McNally, V. A., Ross, G. A., et al. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.24.2024 · Cited by 643
Scheuer, W., Friess, T., Burtscher, H., Bossenmaier, B., Endl, J., & Hasmann, M. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-4597 · Cited by 622
HER2-amplified breast cancer: mechanisms of trastuzumab resistance and novel targeted therapies
Gajria, D., & Chandarlapaty, S. (2011) · Expert Review of Anticancer Therapy · doi:10.1586/era.10.226 · Cited by 494
Metadata
- Authors
- Adams, C. W., Allison, D. E., Flagella, K., Presta, L., Clarke, J., Dybdal, N., McKeever, K., & Sliwkowski, M. X.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2005-09-03
- Volume
- 55
- Issue
- 6
- Pages
- 717-727
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W1989078916
- Cited by
- 316
- References
- 54
- FWCI
- 5.51
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.